TABLE 2.
EFFECTS OF MWCNT EXPOSURE AND OVA SENSITIZATION ON PROSTANOID CONCENTRATIONS DETECTED BY LIQUID CHROMATOGRAPHY–TANDEM MASS SPECTROSCOPY IN BRONCHOALVEOLAR LAVAGE FLUID FROM WILD-TYPE AND COX-2−/− MICE
Genotype | Pretreatment | OPA | PGE2 |
6-keto PGF1α |
PGF2α |
TXB2 |
PGD2 |
|||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 d | 14 d | 1 d | 14 d | 1 d | 14 d | 1 d | 14 d | 1 d | 14 d | |||
WT |
Saline |
Vehicle |
47 ± 16 |
38 ± 6 |
11 ± 5 |
4 ± 2 |
17 ± 1 |
10 ± 1 |
21 ± 7 |
7 ± 1 |
107 ± 26 |
72 ± 15 |
|
Saline |
MWCNT |
56 ± 14 |
59 ± 4 |
11 ± 7 |
7 ± 2 |
12 ± 2 |
13 ± 1 |
14 ± 3 |
11 ± 1 |
72 ± 11 |
85 ± 6 |
|
OVA |
Vehicle |
88 ± 13 |
91 ± 7 |
16 ± 5 |
6 ± 1 |
39 ± 8 |
26 ± 5 |
102 ± 28* |
42 ± 13 |
106 ± 32 |
118 ± 23 |
|
OVA |
MWCNT |
161 ± 68 |
85 ± 12 |
39 ± 16* |
6 ± 1 |
49 ± 16 |
15 ± 1 |
63 ± 20 |
25 ± 7 |
96 ± 32 |
131 ± 19 |
COX-2−/− |
Saline |
Vehicle |
76 ± 9 |
60 ± 8 |
12 ± 5 |
10 ± 4 |
20 ± 4 |
13 ± 2 |
26 ± 6 |
17 ± 5 |
106 ± 17 |
120 ± 25 |
|
Saline |
MWCNT |
98 ± 12 |
91 ± 32 |
14 ± 5 |
11 ± 8 |
19 ± 2 |
18 ± 3 |
24 ± 4 |
23 ± 3 |
137 ± 20 |
170 ± 12* |
|
OVA |
Vehicle |
94 ± 43 |
63 ± 10 |
5 ± 1 |
3 ± 1 |
30 ± 8 |
13 ± 1 |
38 ± 12 |
21 ± 9 |
169 ± 104 |
112 ± 10 |
OVA | MWCNT | 175 ± 42 | 62 ± 7 | 9 ± 3 | 7 ± 3 | 66 ± 13 | 14 ± 1 | 120 ± 36* | 20 ± 1 | 227 ± 97 | 87 ± 11 |
Definition of abbreviations: COX-2, cyclooxygenase-2; d, days; MWCNT, multiwalled carbon nanotubes; OPA; oropharyngeal aspiration; OVA, ovalbumin; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGF2α, prostaglandin F2α; 6-keto PGF1α, 6-keto prostaglandin F1α; TXB2, thromboxane B2; WT, wild-type.
Data are expressed as pg/ml (mean ± SEM). The vehicle consisted of saline/0.1% pluronic solution.
P < 0.05, compared with the corresponding genotype group.